P-129: Study of GnRH Potential in Inhibition of Side Effect of Drugs Used in Chemotherapy on Spermatogenesis

Background: Male factors, mainly spermatogenesis disorder, are responsible for 20-30% of infertility occurs in different societies. One of the known causes of spermatogenesis disorder is chemotherapy in patients with cancer. The side effect of chemotherapic agents may last from 10 years up to the end of the life. Since dividing cells are mainly affected by anticancer drugs, the aim of the present study is to investigate the preventive effect of GnRH antagonist as a suppressor of spermatogonial proliferation, on spermatogenic defect produced by anticancer drug (vincristine). Materials and Methods: In the present study 30 adult male mice aging 6-8 weeks were used. The mice were divided into 3 equal groups as: control, exp I group and exp II group. In exp I group. A single dose of vincristine was injected as ip, at 1.5 mg/kg. In expII group, cetrorelix injection was started one week before vincristine treatment and continued for 3 more weeks. The mice in all groups were sacrificed 3 weeks after the last dose of Cetrorelix injection. Testicular specimens were prepared for LM studies. Results: LM study showed that rate of spermatogonia in control group was 47.42 ± 1.96 μm, in exp I group was16.53 ± 2.37 μm, and in exp II group was 36.28 ± 7.98 μm. The rate of spermatogenesis Index (SI) in control group was 3.03 ± 0.21 μm, and in exp I group was 1.04 ± 0.48 μm, and in exp II group 1.90 ± 0.40 μm. Statistical analysis of data showed significant differences in rate of spermatogonia and SI between control and exp I group (p<0.05).and the rate of spermatogonia in exp II group was similar to control group, but there were significant differences in rate SI between exp II group and control group (p<0.05). Conclusion: According to the result it is concluded that GnRH antagonist administration before cancer treatment could partially prevent the side effect of anticancer drugs.